This Week in European MedTech and HealthTech: 27th February 2026

Nelson Advisors
13 minutes ago
4 min read

Across Europe this week you’re seeing three main HealthTech threads: stepped‑up public funding (notably Ireland’s new ARC Hub), continued tightening of the MDR/IVDR–AI Act regime and selective early‑stage capital going into neuro and infrastructure‑style digital health.

Public funding and hubs

Ireland formally launched the €34.3m ARC Hub for HealthTech, with RCSI and University of Galway as partner institutions, to back research‑led innovation and commercialisation in medtech and digital health.

2026 Horizon Europe “Health” calls went live this month, with topics including digital‑mental‑health harms in youth and long‑COVID, reinforcing EU‑level non‑dilutive capital for data‑ and AI‑heavy health projects.

Regulation and policy

The Commission’s late‑2025 MDR/IVDR “simplification” package is now the reference point in 2026, focusing on streamlined notified‑body oversight, clearer recertification timelines, and more explicit software and cybersecurity requirements for SaMD and connected medtech.

EU AI Act high‑risk provisions for clinical AI are phasing in (full enforcement in March 2026), which is already steering capital toward explainable “glass‑box” models to satisfy transparency and human‑oversight standards.

The new EU Health Technology Assessment Regulation (EU 2021/2282), applicable since January 2025, is bedding in: EMA and HTA bodies will run joint clinical assessments for certain high‑risk devices, impacting evidence packages and pan‑EU pricing/market access strategy.

UK–EU device access

In the UK, MHRA opened a consultation on routes to access medical devices approved in Europe, aiming to leverage EU approvals while maintaining domestic oversight, which matters for EU–UK launch sequencing and label strategy.

Capital flows and startups

Female‑led Danish startup Hemi Health raised c.€4m to scale migraine and concussion digital therapeutics internationally, emblematic of ongoing appetite for neuro and specialty‑care DTx despite a generally disciplined funding climate.

Recent dealflow commentary still highlights capital concentration in regulated adjacencies such as AMR diagnostics, cardiology, and robotics, with rounds like ShanX Medtech’s ~€24m financing cited as representative of early‑2026 medtech funding focus.

Sector‑wide analyses describe 2026 as a “great rationalisation” period: the end of venture‑subsidised experimentation and a stronger “flight to quality” toward assets with robust revenue, regulatory clarity and HTA‑ready data.

Data, EHDS and infrastructure

2026 is being framed as a preparation year for the European Health Data Space, pushing HealthTech and medtech players to prioritise EHDS‑ready data architectures, anonymisation, governance and cross‑border data‑sharing for AI training and validation.

EU‑level programmes are explicitly funding backend “plumbing” such as interoperability layers, real‑time monitoring platforms, remote surgical support, and hospital cybersecurity aligned with EHDS‑style data flows.

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk

>>>>

European MedTech this week is dominated by Brussels‑driven regulatory moves around MDR/IVDR and EUDAMED, plus UK steps to lean on CE‑marked devices, all against a backdrop of “industrial maturity” in funding and capital allocation.

MDR/IVDR and notified bodies

The Commission’s late‑2025 MDR/IVDR simplification proposals are shaping 2026 discussions, targeting streamlined notified‑body oversight, clearer recertification clocks (e.g. 60‑day review, 15‑day certificate issuance), and reduced admin burden while holding safety constant.

A draft Implementing Act on Annex VII requirements for notified bodies aims to harmonise how NBs operate, with more uniform expectations and processes expected to ease capacity constraints and improve predictability for manufacturers.

New harmonised standards under MDR/IVDR (end‑January decisions) now cover neurosurgical implants, biocompatibility, clinical investigations, sterilisation and labelling, tightening the technical baseline for a wide range of device categories.

EUDAMED and 2026 deadlines

Four key EUDAMED modules (actor registration, UDI/devices, notified bodies & certificates, market surveillance) are now confirmed functional, starting a six‑month transition into mandatory use.

From 28 May 2026, new MDR/IVDR devices must be in EUDAMED before EU market entry, with phased timelines for legacy MDD/AIMDD devices, driving manufacturers to accelerate data, UDI and PMS readiness this year.

UK: CE‑mark recognition

MHRA has launched a consultation (running to 10 April 2026) proposing indefinite recognition of CE‑marked devices in Great Britain, dropping earlier plans for a hard switch to standalone UKCA approvals.

The proposal would align GB transitions with EU timelines, introduce an international reliance route for higher‑risk devices, and sit alongside new UK post‑market surveillance rules already in force.

Capital flows and EU‑level funding

Recent medtech deal flow commentary still points to capital concentration in AMR diagnostics, cardiology and robotics, with financings like ShanX Medtech’s c.€24m round used as reference cases for where early‑2026 money is going.

EU‑level programmes (Horizon Europe, EIC STEP and medical‑technology‑specific calls) are actively funding multinational clinical studies for orphan and “breakthrough” devices, including AI‑enabled solutions, with typical grants in the €6–8m range per project and equity cheques of €10–30m for deep‑tech scale‑ups.

Strategic framing: “industrial maturity”

Strategic outlook pieces frame 2026 as a “great rationalisation” or industrial maturity phase for European MedTech: less appetite for speculative, pre‑evidence device plays and more emphasis on profitable efficiency, robust PMS and HTA‑ready clinical data.

The AI Act’s 2026 high‑risk enforcement timeline is now a binary filter for device‑integrated AI: only teams with strong data governance, documentation and human‑oversight architectures are seen as bankable medtech targets.

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech